Since 1987, Oxford University Innovation has been responsible for creating spinout companies based on academic research generated within and owned by the University of Oxford, and in recent years has spun out 15-20 new companies every year.
Over £2.5bn in external investment has been raised by Oxford University Innovation spinouts since 2010, and ten of our current portfolio are currently listed in London and New York.
The creation of new spinout companies, most of which are listed below, also channels millions of pounds back into University research, benefits local economic development and has created many new jobs in the region.
Celleron is an oncology healthcare company that has developed biomarkers using epigenetic techniques that match drugs to responsive disease.
Incorporated in November 2005
Origin: Oxford University, Sir William Dunn School of Pharmacology
Circadian Therapeutics identify and bring to market pharmaceutical and diagnostic platforms for the effective management of physiological and pathological conditions through their ability to modify the body's circadian rhythms.
Incorporated in September 2016
Origin: Oxford University, Ophthalmology
ClinOx offers clients knowledge and expertise in the development, placement, conduct and analysis of early phase oncology clinical trials, with particular emphasis on pharmacokinetic and mechanistic endpoints.
Origin: Oxford University, Nuffield Division of Clinical and Laboratory Sciences
Cocotec builds software tools, which harness the power of automated formal verification. Its product, the Coco Platform, comes with a powerful software development environment that enables developers to build their software, automatically verify whether it is correct, and then generate high quality reliable code.
Incorporated in November 2018
Origin: Oxford University, Department of Computer Science